Skip to main content

Table 1 Patient demographics and baseline characteristics for all prospective patients based on index therapy

From: Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

  All prospective patients (N = 1356) IPI-treated cohort Non-IPI–treated cohort
IPI-noOther (n = 780) IPI-Other (n = 314) Other-Other (n = 205) Other-IPI (n = 57)
Median age, years (range) 64 (22–90) 65 (22–90) 62 (25–88) 63 (24–89) 60 (27–84)
Sex, no. (%)
 Male 819 (60) 483 (62) 178 (57) 118 (58) 40 (70)
 Female 537 (40) 297 (38) 136 (43) 87 (42) 17 (30)
Race, no. (%)
 White 1300 (96) 746 (96) 300 (96) 200 (98) 54 (95)
 Asian 3 (<  1) 2 (<  1) 0 0 1 (2)
 Other 7 (1) 6 (1) 1 (<  1) 0 0
 Not specified 46 (3) 26 (3) 13 (4) 5 (2) 2 (4)
Geographic region, no. (%)
 Europe 1061 (78) 641 (82) 231 (74) 149 (73) 40 (70)
 North America 170 (13) 67 (9) 64 (20) 29 (14) 10 (18)
 Rest of world 125 (9) 72 (9) 19 (6) 27 (13) 7 (12)
Time on study,a months
 Mean (SD) 10 (11) 9 (10) 14 (11) 9 (10) 13 (9)
 Median (range) 6 (0–50) 5 (0–46) 10 (1–39) 5 (0–38) 9 (2–50)
Previous systemic therapy for advanced melanoma, no. (%)
 Yes 1064 (78) 619 (79) 233 (74) 169 (82) 43 (75)
 No 292 (22) 161 (21) 81 (26) 36 (18) 14 (25)
BRAF mutation status, no. (%)
 Mutant 542 (40) 262 (34) 135 (43) 116 (57) 29 (51)
 Wild-type 743 (55) 471 (60) 162 (52) 84 (41) 26 (46)
 Inconclusive/unknown 12 (1) 8 (1) 3 (1) 1 (< 1) 0
 Missing 59 (4) 39 (5) 14 (4) 4 (2) 2 (4)
ECOG PS, no. (%)
 0 470 (35) 274 (35) 134 (43) 47 (23) 15 (26)
 1 328 (24) 208 (27) 59 (19) 48 (23) 13 (23)
 2 63 (5) 35 (4) 5 (2) 22 (11) 1 (2)
 3 13 (1) 3 (<  1) 0 8 (4) 2 (4)
 4 2 (<  1) 1 (<  1) 0 1 (<  1) 0
 Missing 480 (35) 259 (33) 116 (37) 79 (39) 26 (46)
Disease stage, no. (%)
 Stage III 44 (3) 26 (3) 10 (3) 3 (1) 5 (9)
 Stage IV 1312 (97) 754 (97) 304 (97) 202 (99) 52 (91)
Metastases stage, no. (%)
 M0 43 (3) 25 (3) 10 (3) 3 (1) 5 (9)
 M1a 150 (11) 85 (11) 41 (13) 22 (11) 2 (4)
 M1b 247 (18) 144 (18) 69 (22) 29 (14) 5 (9)
 M1c 638 (47) 382 (49) 143 (46) 85 (41) 28 (49)
 CNS 278 (21) 144 (18) 51 (16) 66 (32) 17 (30)
CNS metastases,b no. (%)
 Symptomatic 85 (31) 42 (29) 16 (31) 22 (33) 5 (29)
 Asymptomatic 193 (69) 102 (71) 35 (69) 44 (67) 12 (71)
LDH status at study entry, no. (%)
 Normal 542 (40) 298 (38) 159 (51) 64 (31) 21 (37)
 Elevated or outside of normal 531 (39) 310 (40) 105 (33) 92 (45) 24 (42)
 Not assessed 283 (21) 172 (22) 50 (16) 49 (24) 12 (21)
  1. CNS central nervous system, ECOG PS Eastern Cooperative Oncology Group performance status, IPI ipilimumab, LDH lactate dehydrogenase, SD standard deviation.
  2. aDefined as the time from study completion/discontinuation/death/data cut date (whichever came first) − the index therapy date + 1; study time for a patient may have exceeded 1065 days
  3. bThe number of patients who reported the CNS as the site of distant metastasis was used as the denominator